Clinical Trial Update: Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis [Phase 2]

View source ↗

Summary

This update notes that a Phase 2 trial evaluating Tarperprumig for safety and efficacy in adults with ANCA-associated vasculitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Drugs mentioned

• Tarperprumig

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Status: RECRUITING